A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, PK, and PD Study of CNF2024 Administered Orally Twice Weekly for 3 Weeks of a 4 Week Course or Twice Weekly for 4 Weeks of a 4 Week Course to Patients With Advanced Solid Tumors

Inclusion Criteria:

- Histologically or cytologically confirmed solid tumor which has failed standard
therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which
effective therapy is not available

- At least 18 years of age

- Hematology: Absolute neutrophil count (ANC) > 1500 cells/mm3, platelet count >
100,000 cells/mm3 and hemoglobin >= 9 gm/L

- Hepatic: Bilirubin < 1.5 X upper limit of normal (ULN); alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver
metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) < 5.0 X ULN.

- Renal: Serum creatinine levels < 2.0 mg/dL or creatinine clearance > 60 mL/min

- Coagulation: international normalized ratio (INR) < 1.5 times normal

- Adrenal: Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels

- Normal electrocardiogram (ECG) with QTc <= 450 msec for men and <= 470 msec for women

- Estimated life expectancy of at least 3 months as determined by the Investigator

- Eastern Cooperative Oncology Group (ECOG) performance status <= 2

- Male and female patients of childbearing potential must practice effective
double-barrier contraception during the study and continue contraception for 3 months
after their last dose of study drug. Male patients must agree to not have
intercourse with pregnant or nursing women during the study and for 3 months after
their last dose of study drug, unless using double-barrier contraception. The only
exceptions to double-barrier contraception are: Patient or partner is surgically
sterile,female patient is postmenopausal for at least 1 year before screening or
patient abstains from sexual intercourse, at the discretion of the Investigator

Exclusion Criteria:

- Pregnant or nursing women, women of child-bearing age not using reliable means of
contraception.

- Radiotherapy or chemotherapy within the previous 28 days. Recovery to Grade 1 or less
from chemotherapy-induced toxic effect, except alopecia, is required.

- Participation in any investigational drug study within 28 days prior to CNF2024
administration

- Active infection requiring intravenous antibiotic treatment

- Patients with second malignancy requiring active treatment (except hormonal therapy)

- Concurrent severe or uncontrolled medical disease (i.e., systemic infection,
diabetes, hypertension, coronary artery disease, congestive heart failure)

- Active symptomatic fungal, bacterial and/or viral infection including active HIV or
viral (A, B or C) hepatitis

- Problems with swallowing or malabsorption

- Chronic diarrhea (excess of 2-3 stools/day above normal frequency)

- Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease,
or hemorrhagic coloproctitis

- Major surgery of the stomach or small intestine

- Adrenal dysfunction > Grade 2

- Patients with diabetes (your doctor will discuss if you are eligible for this study)